What's Happening?
Ractigen Therapeutics has announced the publication of a peer-reviewed paper in Nature Medicine detailing the preclinical and First-in-Human clinical data for RAG-17, a small interfering RNA (siRNA) therapy targeting amyotrophic lateral sclerosis (ALS)
caused by mutations in the SOD1 gene. The study highlights the use of Ractigen's Smart Chemistry-Aided Delivery (SCAD™) platform, which allows for effective delivery of siRNA to the central nervous system (CNS). The First-in-Human trial demonstrated that RAG-17 met primary safety endpoints with no serious adverse events and showed significant reductions in key biomarkers, including a 69% decrease in cerebrospinal fluid SOD1 protein and a 62% decrease in plasma neurofilament light chain (NfL). The preclinical models also showed unprecedented survival extension and functional rescue in advanced disease stages.
Why It's Important?
The development of RAG-17 represents a significant advancement in the treatment of SOD1-ALS, a rapidly progressive and devastating disease. The positive clinical data suggest that RAG-17 could become a best-in-class disease-modifying therapy, offering improved potency, durability, and patient convenience compared to existing treatments. This could potentially transform the therapeutic landscape for ALS patients, providing a more effective and less frequently dosed treatment option. The success of RAG-17 also validates the SCAD™ platform, which could be applied to other RNA-based therapies, potentially benefiting a broader range of neurological and genetic disorders.
What's Next?
Ractigen Therapeutics plans to advance RAG-17 through further clinical trials to confirm its efficacy and safety in a larger patient population. The company aims to bring this promising therapy to the SOD1-ALS community, addressing the unmet medical needs of patients with this challenging condition. Continued research and development will focus on optimizing dosing regimens and exploring the potential of the SCAD™ platform for other therapeutic applications.
